Adrenoleukodystrophy Market Size, Share, Trend, Epidemiology, Market Forecast by Delveinsight
- Ankit Nigam
- May 8, 2020
- 5 min read
DelveInsight's "Adrenoleukodystrophy - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adrenoleukodystrophy , historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
In 2017, the total prevalent population of ALD in the 7MM was 55,242.
The estimates show highest diagnosed prevalence of ALD in the United States with 4,885 cases in 2017.
In 2017, the prevalent population of ALD in the US was 19,371.
Japan ranked second among the 7MM in terms of prevalent cases for ALD.
Adrenoleukodystrophy market report covers a descriptive overview and comprehensive insight of the Adrenoleukodystrophy epidemiology and Adrenoleukodystrophy market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
Adrenoleukodystrophy market report provides insights on the current and emerging therapies.
Adrenoleukodystrophy market report offers a global historical and forecasted market covering drug outreach in 7 MM.
Adrenoleukodystrophy market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Adrenoleukodystrophy market.
“DelveInsight’s epidemiology model for ALD estimates that out of the total population of 19,371 cases in the US for ALD, 7,750 cases and 11,621 cases were contributed by males and females, respectively.”
Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity.
The disease mainly affects males (hemizygotes), but similar to other X-linked disorders, it is increasingly recognized that females (heterozygotes) may be clinically affected as well.
The main neurological manifestations include a progressive, fatal, inflammatory cerebral leukodystrophy (cerebral adrenoleukodystrophy) most frequently appearing in young boys, and a slowly progressive, non-inflammatory axonal myelopathy and peripheral neuropathy (adrenomyeloneuropathy, AMN), that occurs in most adult males. Many females develop myeloneuropathy as well, but usually at a later stage and with milder symptoms than seen in males. Furthermore, the disorder manifests with primary adrenal failure (PAI) in more than half of the males that are usually not seen in females.
Neonatal
Childhood
Adult-Onset
“According to the DelveInsight’s Analysts, the market size of ALD was USD 922.43 million in 2017.”
Bluebird Bio
Minoryx Therapeutics
MedDay Pharmaceutic als
Magenta Therapeutics
SOM Biotech
Orpheris Inc.
And Many Others.
The launch of the emerging therapies is expected to significantly impact the Adrenoleukodystrophy treatment scenario in the upcoming years:-
Lenti D
Leriglitazone
MD1003
MGTA-456
SOM1201
OP-101
And Many Others.
Key Insights
Adrenoleukodystrophy (ALD): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of ALD in 2017
2.2. Total Market Share (%) Distribution of ALD in 2030
Adrenoleukodystrophy: Disease Background and Overview
3.1. Introduction
3.2. Clinical aspects of ALD
3.3. Causes of ALD
3.4. Inheritance pattern of ALD
3.5. ALD-Symptoms
3.6. Pathogenesis and Pathophysiology of ALD
3.7. Diagnosis
3.7.1. ALD Newborn Screening
3.7.2. Tools for evaluating Cerebral ALD
3.7.3. Diagnostic algorithm
3.7.4. HSCT and presymptomatic diagnosis of ALD in Japan
Epidemiology and Patient Population
4.1. Key Findings
4.2. Epidemiology Methodology
4.3. KOL Views
4.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM
United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States
5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States
5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States
5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States
EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of Adrenoleukodystrophy in Germany
6.1.3. Gender-specific Prevalence of Adrenoleukodystrophy in Germany
6.1.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany
6.1.5. Type-specific Diagnosed Prevalence of ALD in males in Germany
6.2. France Epidemiology
6.2.1. Assumptions and rationale
6.2.2. Total Prevalent Population of Adrenoleukodystrophy in France
6.2.3. Gender-specific Prevalence of Adrenoleukodystrophy in France
6.2.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France
6.2.5. Type-specific Diagnosed Prevalence of ALD in Males in France
6.3. Italy Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Prevalent Population of Adrenoleukodystrophy in Italy
6.3.3. Gender-specific Prevalence of Adrenoleukodystrophy in Italy
6.3.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy
6.3.5. Type-specific Diagnosed Prevalence of ALD in Males in Italy
6.4. Spain Epidemiology
6.4.1. Assumptions and Rationale
6.4.2. Total Prevalent Population of Adrenoleukodystrophy in Spain
6.4.3. Gender-specific Prevalence of Adrenoleukodystrophy in Spain
6.4.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain
6.4.5. Type-specific Diagnosed Prevalence of ALD in Males in Spain
6.5. United Kingdom Epidemiology
6.5.1. Assumptions and Rationale
6.5.2. Total Prevalent Population of Adrenoleukodystrophy in the United Kingdom
6.5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United Kingdom
6.5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United Kingdom
6.5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United Kingdom
Japan Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalent Population of Adrenoleukodystrophy in Japan
7.3. Gender-specific Prevalence of Adrenoleukodystrophy in Japan
7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan
7.5. Type-specific Diagnosed Prevalence of ALD in Males in Japan
Current Treatment and Medical Practices
8.1. Subtype-specific Treatment
8.2. Treatment Guidelines
8.2.1. Recommendations for Treatment of X-linked ALD in the United States
8.2.2. Adrenoleukodystrophy treatment: European Leukodystrophies Association
8.3. Early intervention and long-term follow-up system for presymptomatic ALD patients in Japan
Unmet Needs
Emerging Therapies
10.1.Lenti D: bluebird bio
10.1.1. Drug Description
10.1.2. Regulatory Milestone
10.1.3. Other Development Activities
10.1.4. Clinical Development
10.1.5. Safety and Efficacy
10.1.6. Advantages and Disadvantages
10.1.7. Product Profile
10.2.Leriglitazone: Minoryx Therapeutics, S.L.
10.2.1. Drug Description
10.2.2. Regulatory Milestones
10.2.3. Other Development Activities
10.2.4. Clinical Development
10.2.5. Safety and Efficacy
10.2.6. Advantages and Disadvantages
10.2.7. Product Profile
10.3.MD1003: MedDay Pharmaceuticals
10.3.1. Drug Description
10.3.2. Other Development Activities
10.3.3. Clinical Development
10.3.4. Safety and Efficacy
10.3.5. Advantages and Disadvantages
10.3.6. Product Profile
10.4.MGTA-456: Magenta Therapeutics
10.4.1. Product Description
10.4.2. Other Development Activities
10.4.3. Clinical Development
10.4.4. Clinical Trial Update
10.4.5. Safety and Efficacy
10.4.6. Product Profile
10.5.OP-101: Orpheris Inc.
10.5.1. Drug Description
10.5.2. Regulatory Milestones
10.5.3. Other Development Activities
10.5.4. Clinical Development
10.5.5. Product Profile
10.6.SOM1201: SOM Biotech
10.6.1. Product Description
10.6.2. Other Development Activities
10.6.3. Product Profile
Adrenoleukodystrophy (ALD): 7MM Market Analysis
11.1.Key Findings
11.2.Market Methodology
11.3.Market Size of Adrenoleukodystrophy in the 7MM
11.4.Market Size of Adrenoleukodystrophy by Therapies in the 7MM
7MM: Market Outlook
United States
13.1.United States Market Size
13.1.1. Total Market size of Adrenoleukodystrophy in the United States
13.1.2. Market Size of Adrenoleukodystrophy by Therapies in the US
EU-5 countries
14.1.Germany Market Size
14.1.1. Total Market size of Adrenoleukodystrophy in Germany
14.1.2. Market Size of Adrenoleukodystrophy by therapies in Germany
14.2.France Market Size
14.2.1. Total Market size of Adrenoleukodystrophy in France
14.2.2. Market Size of Adrenoleukodystrophy by therapies in France
14.3.Italy Market Size
14.3.1. Total Market size of Adrenoleukodystrophy in Italy
14.3.2. Market Size of Adrenoleukodystrophy by therapies in Italy
14.4.Spain Market Size
14.4.1. Total Market size of Adrenoleukodystrophy in Spain
14.4.2. Market Size of Adrenoleukodystrophy by therapies in Spain
14.5.United Kingdom Market Size
14.5.1. Total Market size of Adrenoleukodystrophy in the United Kingdom
14.5.2. Market Size of Adrenoleukodystrophy by therapies in the UK
Japan
15.1.Japan Market Size
15.1.1. Total Market size of Adrenoleukodystrophy in Japan
15.1.2. Market Size of Adrenoleukodystrophy by therapies in Japan
Market Drivers
Market Barriers
Appendix
18.1.Bibliograpgy
18.2.Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
Related Reports:
The Adrenoleukodystrophy report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Adrenoleukodystrophy across the complete product development cycle, including all clinical and nonclinical stages.
The Adrenoleukodystrophy epidemiology covered in the report provides historical as well as forecasted Adrenoleukodystrophy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
Comments